Overview

A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
A prospective, open-label, multi-center, Phase I/II study of L19IL2 in combination with Dacarbazine in patients with metastatic melanoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Philogen S.p.A.
Treatments:
Antibodies
Antibodies, Monoclonal
Immunoglobulins
Interleukin-2